- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
112.5Iu r-hFSH starting dose enough for successful IVF in Amh ≥3 ng/ml: FertSert
Controlled ovarian hyperstimulation(COH) is needed in order to improve the pregnancy rate in IVF cycles. Recently, there has been an interest in using a much lower dosage of FSH for mild stimulation in IVF protocols. The purpose of this study was to assess the mild stimulation with starting dose of recombinant human FSH (r-hFSH) 112.5IU could be enough for successful IVF outcomes in patients with AMH ≥3ng/ml in IVF cycles.
Authors retrospectively reviewed 657 consecutive cycles of 594 normo-ovulatroy women(AMH ≥3ng/ml) who underwent IVF treatment over a 3-year period (2010 –2012) at their institution. Study population was divided into two groups according to r-hFSH starting dose for COH-IVF cycles.
Group A: r-hFSH(Gonal-F) starting dose 112.5IU (n=257), Group B: starting dose 150IU (n=400) in women with AMH ≥3ng/ml. Outcomes were compared the number of oocytes retrieved, total dose of r-hFSH, total r-hFSH stimulation days, clinical pregnancy and abortion rate between the two groups.
The total dose of r-hFSH administered was significantly different between the group A and the group B (1055.1 IU and 1365.5 IU, p<0.01). The total number of r-hFSH administration days (9.6days (5–17) and 9.1days (9–16), p=0.08) and embryo quality were comparable in both groups.
Although the number of retrieved oocytes (14.9 6.8 vs. 13.3 6.1, P>0.01) and fertilized oocytes(9.1 4.9 vs. 8.8 4.3, P=0.02) were significantly higher in group A than group B.
However, the pregnancy rate (63.4% vs 58.3%, p¼0.139) and abortion rate (12.9% vs13.3%) were not significantly different between both groups.
In study results, a total mean r-hFSH dose of 1055.1IU with the 112.5IU starting dose in COH cycle was sufficient for the number of retrieved oocytes and the pregnancy rates in patients with AMH ≥3ng/ml. Therefore, These seems clear that a subset of patients with AMH ≥ng/ ml undergoing ovarian stimulation can be adequately treated with a 112.5 IU starting dose of r-hFSH.
Source: S. G. Kim, J. H. Lee, I. H. Park;FertilitySterility
MBBS, MD Obstetrics and Gynecology
Dr Nirali Kapoor has completed her MBBS from GMC Jamnagar and MD Obstetrics and Gynecology from AIIMS Rishikesh. She underwent training in trauma/emergency medicine non academic residency in AIIMS Delhi for an year after her MBBS. Post her MD, she has joined in a Multispeciality hospital in Amritsar. She is actively involved in cases concerning fetal medicine, infertility and minimal invasive procedures as well as research activities involved around the fields of interest.